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Abstract
Background: As people age, they become increasingly vulnerable to the untoward effects of medicines due to changes in
body systems. These may result in medicines related problems (MRPs) and consequent decline or deterioration in health.
Aim: To identify MRPs, indicators of deterioration associated with these MRPs, and preventative interventions from the liter-
ature. Design and Setting: Systematic review of primary studies on MRPs originating in Primary Care in older people.
Methods: Relevant studies published between 2001 and April 2018 were obtained from Medline (via PubMed), CINAHL,
Embase, Psych Info, PASCAL, Scopus, Cochrane Library, Science Direct, and Zetoc. Falls, delirium, pressure ulcer, hospitalization,
use of health services and death were agreed indicators of deterioration. The methodological quality of included studies was
assessed using the Down and Black tool. Results: There were 1858 articles retrieved from the data bases. Out of these, 21 full
text articles met inclusion criteria for the review. MRPs identified were medication error, potentially inappropriate medicines,
adverse drug reaction and non-adherence. These were associated with indicators of deterioration. Interventions that involved
doctors, pharmacists and patients in planning and implementation yielded benefits in halting MRPs. Conclusion: This Systematic
review summarizes MRPs and associated indicators of deterioration. Appropriate interventions appeared to be effective against
certain MRPs and their consequences. Further studies to explore deterioration presented in this systematic review is imperative.
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Introduction
Ensuring the safety of medication use in older people can often
be challenging as older people often have several coexisting
medical problems and take multiple drugs. Other reported, fea-
tures that can be important to older people in terms of medi-
cines handling are reduced mobility, reduced cognition, as well
as increased frailty.1 Furthermore, body system changes that
occur with aging can contribute to this difficulty in medicines
handling.2 Central to health and care of some older people is
the management of a variety of medical conditions commonly
referred to as “geriatric syndrome” (GS) which can include fall,
delirium, pressure ulcer and underfeeding.3 Sanchez et al
(2011)4 reported a prevalence of 60.2% geriatric syndrome in
older patients with acute cardiac disease. On the other hand,
Nair, and Colleagues (2008)5 reported a GS prevalence of
between 29% (cognitive impairment including delirium and
dementia) and 54% (Fall) in older patients admitted to a tertiary
hospital. This implies that GS is common in older people. This
syndrome can develop when compensatory abilities of older
people decline or become compromised by accumulated
impairment in multiple areas of the body otherwise referred
to as frailty.6 This syndrome can also be a consequence of
medication use, which as a result, has potential for medicines
related problems (MRPs) and harm.7 Undoubtedly, unchecked
MRPs can lead to deterioration in health and death.8 Medicines,
medication, or drug related problem (DRP) are terms that have
been used in different studies to refer to the same concept.
An MRP or a DRP as referred to by Hepler & Strand (1990)8
is defined as “an event or a circumstance involving drug treat-
ment that actually or potentially interferes with the patient
experiencing optimum outcome of medical care.”8 On the other
hand, deterioration in health has been defined as clinical
decline or onset of sudden acute episodes of ill health.9 Hence
falls, delirium, increased use of health care services, and hos-
pitalization which can culminate in death can be considered as
markers of deterioration in health. Studies indicate that certain
MRPs are associated with increased use of health care services
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and hospitalization in older people.10,11 Similarly, clinical
decline in older people, has been shown to result in hospitaliza-
tion more so when the events are of sudden or acute onset.12
Indeed, results from one published systematic review sug-
gested that the prevalence of hospitalization from MRPs can
be up to 12.1%.13 The implication of these findings is that
MRPs and clinical decline can be associated with hospitaliza-
tion of affected individuals. Sadly, hospitalization often trans-
lates to some form of cost to the patient as well as translating to
an economic cost that can be worrying for any health care
system.14 Thus, the annual cost of hospital admissions associ-
ated with one type of MRPs, notably adverse drug reaction
(ADR), was estimated to be £466 m (US $847 m) by an English
study undertaken over a decade ago.11 Similarly, a rapid evi-
dence synthesis and economic analysis of studies published
about a decade ago, estimated the cost of avoidable Primary
care ADR to be £83.7 m (US$150.66 m) per annum.14 In
terms of global estimate, worldwide, the annual cost associated
with medication errors (one other type of MRPs) was £23
billion (US$42 billion).15 This constituted almost 1% of the
total global health expenditure.15 It would be appropriate to
suggest that the cost associated with MRPs makes the study
of MRPs and of the preventative interventions to mitigate it
imperative. This is a global necessity, given both an increasing
age demographic and scarce resources, more so since events
due to MRPs are potentially preventable.14-16 Importantly,
most medicines related problems that can lead to hospitaliza-
tion resulting in a cascade of problems within hospitals have
their origin within primary care setting.17 Hence it is fitting to
have this study on MRPs originating in Primary care. A number
of systematic reviews have explored aspects of medicines
related problems occurring outside secondary care settings and
leading to hospitalization and /or death. Others, however
reported prevalence of MRPs without health outcome associ-
ated with it. Thus, a systematic review by Morin, Laroche,
Taxier and Johnell (2016)18 reported a 43.2% weighted point
prevalence of potentially inappropriate medicine (PIM) in nur-
sing home. However, it did not explore its impact on health of
older adults, an assessment important for health-related econ-
omy. Another systematic review reported a higher rate of hos-
pitalization in nursing home residents exposed to PIM when
compared to those in the community.19 Similarly, there are
published systematic reviews on interventions to improve poly-
pharmacy in older people.20,21 Hence it can be right to say that
several works including systematic reviews had been under-
taken on medicines related problems in older people. However,
none to the knowledge of the reviewers explored within one
systematic review several MRPs occurring in older people aris-
ing in primary care and indicators of deterioration that can
potentially be associated with them as explored in this review.
This is important given that a cohort of patients can often
present with different types of MRPs leading to hospitalization,
use of other health services or death. Furthermore, systematic
review is considered a gold standard for evidence-based
practice.22
Aim: To explore published primary studies on MRPs occur-
ring in older people from Primary health care settings, includ-
ing where this has led to hospitalization; to explore the types of
tools/interventions employed to identify and prevent MRPs in
this patient group.
Review Objectives: To ascertain from published studies,
medicines related problems associated with priorly determined
indicators of deterioration, most frequently affected patient
group reported, the residential settings of these patients, risk
factors, tools employed to identify MRPs, and interventions
applied to prevent MRPs
Methods: The scope of the review was defined by applying
the acronym PICOS (Population, Intervention/Exposure, com-
parison, Outcome, Setting).23 Subsequent to this, though a pro-
tocol was not registered, a systematic review plan guided by
PRISMA-P (Preferred Reporting Items for systematic review for
protocols) was drawn up and approved by the research team
prior to the commencement of the systematic review.24 The plan
was employed as a guidance document to systematically review
relevant Primary studies published between 2001 and 2018. It
described the scope, rational, intended purpose, as well as the
methodological and analytical approach to the review. Ethical
approval was not required prior to commencement of review as
the use of patients’ identifiable data was not intended.
Inclusion Criteria
The agreed indicators for deterioration were fall, delirium,
pressure ulcers, hospitalization, use of health services and
death, chosen because of the association of these indicators
with older people.4,5 Selected studies were assessed against the
following inclusion criteria: (i) Studies written in English lan-
guage; (ii) Population of people aged 65 years and over; (iii)
with an exposure to or intervention for medicines related prob-
lems originating in Primary care;(iv) with outcomes- hospita-
lization, use of health services, falls, delirium, pressure ulcers
or death; (v) Primary studies (vi) Published between 2001 and
2018. Includable study designs were observational (retrospec-
tive or prospective case control, case series non- interventional,
cross sectional, cohort) and interventional (quasi-experimental,
randomized controlled trials, case series interventional) stud-
ies. Studies from year 2001 were included in this review to
make the included studies contemporary with the UK’s initia-
tives on medicines management for older people.25 This was an
initiative, included in the first official document on health and
social care for older people in the UK (National service frame-
work for older people). Put succinctly, it was about using right
medicines in the right context (people and time). Although this
document was initiated in the UK, it has global relevance as
medication use and old age are common issues globally.
Exclusion Criteria
Any study that did not fulfill criteria for inclusion, studies
unrelated to review objectives, abstract -only papers, none-
human subject studies, systematic review studies.
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Data Sources and Search Methods
Electronic search of International Pharmaceutical Abstracts,
MEDLINE (via PubMed), CINAHL, Embase, Psych INFO, PAS-
CAL, SCOPUS, Cochrane Library, Science Direct and Zetoc as
well as references within included articles were undertaken for
relevant studies (Table 1). Choices of data bases to be searched
werebased on insights gained from themethod’s sectionof related
reviews. All data bases were searched from 2001 to March 2018.
MRPs, medicines related problems, medication error,
adverse drug event, adverse drug reaction, non-adherence,
potentially inappropriate medicines, and pharmaceutical care
issues, identified within the MEDLINE database through the
MeSH term “pharmaceutical services,” were employed as
search terms for MRPs. Falls, delirium, pressure ulcers, hospi-
talization, use of health services, and death were employed as
search terms for indicators of deterioration. Settings were spec-
ified as primary care, general practice, family practice, care
homes, community, patient admission, and patient discharge.
Boolean operators, AND/OR were used to combine search
terms. The “snowballing” strategy, going through the reference
list of all included studies to obtain further relevant studies was
also employed26
Study Selection and Validation Process
Following a literature search of the databases by one reviewer
(RO), studies were exported to Endnote X7. Titles and abstracts
were screened for relevance, duplicates were removed fol-
lowed by screening the complete articles for possible inclusion
by one reviewer (RO). Another reviewer, (NU) independently
reviewed the titles, abstracts, and full studies, confirmed rele-
vance of studies in meeting the inclusion criteria and excluded
studies deemed to be irrelevant. There was complete agreement
on relevance of selected studies by RO and NU.
Methodological Quality (Risk of Bias
Assessment)
A quality assessment checklist proposed by Downs and Black
for the methodological quality of randomized and non-
randomized studies of health care interventions was adapted
for this review.27 It is a commonly used and well validated
rating scale.28,29 The original scale assigns a total score out
of 32 points. In line with previous studies, a modified version
of the scale was employed by simplifying the power question
and awarding a single point to studies with sufficient power to
detect a clinically important effect, where the probability value
for a difference being due to chance is <5%.30 The review team
acknowledged that statistical significance does not always
equate to clinical significance.31
Though ROBINS-1 is usually, the preferred tool for
assessing risk of bias in non-randomized trials, the decision
on choice of tool for this review was based on the included
studies comprising of both randomized and non-randomized
studies.
Data Extraction and Synthesis Process
Data extraction forms were created consisting of study design,
setting, mean age, sample size, MRPs, outcome deterioration,
implicated medicines, risk factors and reported interventions
presented in Tables 2 and 3, respectively. Three studies were
initially piloted to test the forms. Data was extracted into these
forms. Data obtained from similar research settings were
grouped together and summarized using narrative synthesis.
Meta-analysis could not be performed because of the hetero-
geneity of the included studies.
It is necessary to note here that since adverse drug event
(ADE) was not categorized in the Hepler and Strand 1990
classification of MRPs unlike ADR, for this review an ADR
will refer to either ADE or ADR.8 An adverse drug event is
defined as an injury resulting from medical intervention
related to drug(s).32 On the other hand, ADR is “an appre-
ciably harmful or unpleasant reaction, resulting from inter-
ventions relating to the use of a medicinal product which
predicts hazard from future administration and warrants pre-
vention or specific treatment or alteration of the dosage
regimen, or withdrawal of the product.”33 This is a compre-
hensive definition that can apply both to adverse drug
events and reactions.
Table 1. Data Base and Terms Employed to Obtain Relevant Studies.
Data bases searched
(From 2001 - March 2018) Terms used for searching in medline
 MEDLINE via PubMed










 Population: Older OR elderly OR (older people) OR (older person) OR (older population) OR (elderly
people) OR (elderly person) OR (elderly population) AND
 Intervention/Exposure: Medicines Related Problems (MRPs) OR (Adverse drug event) OR (adverse drug
reaction) OR (inappropriate medi$) OR (pharmaceutical care issues) OR (pharmaceutical services) OR
(medication error) AND
 Outcomes events: (Pressure ulcer) OR (geriatric syndrome) OR delirium OR fall OR fracture OR hospitali?
ation OR death AND
 Setting: (Primary care) OR (Primary health care) OR (general practice) OR (family practice) OR (patient
admission) OR (patient discharge) OR (continuity of patient care) OR (doctor’s office) OR (ambulatory
care) OR (accident and emergency) OR surgery































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1 provides an overview of the search and selection
process. A total of 1858 studies were identified, of which 21
studies satisfied the inclusion criteria. The included studies
consist of 16 studies on deterioration due to MRPs and 5 studies
on interventions to prevent deterioration due to MRPs. The
included studies consisted of six prospective observational
studies Australia,34 Austria35 Germany,36 Netherlands,5,37
UK.11 Four retrospective cohort studies, Finland,38 Germany,39
Ireland,40 UK.41 Four randomized controlled trials, Canada,42
Sweden,43 Taiwan44 UK.8 Two case control studies, Canada,14
Netherlands.45 One prospective case series intervention, Tai-
wan.46 One mixed methods study UK.47 One qualitative case
study, UK.48 Two secondary data analysis, USA.49,50
The studies were conducted in three types of settings: Care
home16,47,50 Hospital (where MRPs originated from primary
care)11,35,37,38,45,48 and Community (with type of community
setting unspecified).34,40 A UK retrospective cohort study41
included participants from care homes and their own homes
but for this review is reported under care home. On the average,
patients were aged 75 years based on 15 studies.
Methodological Quality of studies: Table 4: Assessment of
methodological quality for 20% of included studies was
achieved using adapted tool.27 All studies were rated and
assigned a grade of “good” (19-23 points).
MRPs in Care Home Setting (Including Nursing
and Residential Homes)
The reported prevalence of MRPs was 9.8% to 69.5%. The MRPs
reported were Potentially Inappropriate Medicines (PIM),41,50
Medication error (ME)47 and adverse drug reaction (ADR).16
Two studies examined the association between PIM and risk
of hospitalization and death. The Beer criteria which is a tool
by American Geriatric Society for identifying potentially inap-
propriate medication use in older adult was used. Descriptive
statistics was used to establish associations between PIM and risk
of hospitalization and death50; lack of association between PIM
and death but an association between number of medicines and
death.41 According to findings from one study, the risk of hospi-
talization was 33% and risk of death was 28% greater for residents
with PIM exposure when compared to those without.50
One study examined ME and reported the potential for harm
through prescribing, monitoring, administration and dispensing
errors.47 One study reported ME as a cause of ADR resulting in
delirium, fall, fall with fracture and death.16 Types of drugs impli-
cated in MRPs were cardiovascular drugs16,47 Anticoagulants, anti-
psychotics, and long-acting benzodiazepines.16,50 Other implicated
medicines identified by single studies were anti-infectives and anti-
epileptics,16 antihistamine with strong anticholinergic effect, nar-
cotics, antispasmodic agents, and iron supplements50
The most at-risk groups were those taking drugs from sev-
eral drug classes16; patients experiencing intermittent use of
PIM50; patients on polypharmacy.16,41
MRPs in Hospital Setting
The reported prevalence of MRPs presented at hospitals from
primary care was 6.5% to 48.7%. The MRPs reported were
PIMs,36,39,45 Potential prescription omission (PPO),45
ADR,5,11,35,37,39,49 unintentional overdose49 and ME.5,37
Two studies examined association between PIM and risk of
hospitalization. These two studies used PRISCUSS List which
was developed specifically for use in Germany to identify PIM
in the elderly.
Multivariate regression was used to establish association.36,39
One study examined association between PIM/PPO and risk of
hospitalization, it used STOPP (Screening Tool of Older persons
Prescription for identifying potentially inappropriate medicines)/
START (Screening Tool to Alert doctors to Right Treatment for
identifying potentially prescription omission) criteria 2008 to
identify PIMs and PPOs, similarly, multivariate regression was
used to establish association.45 However, when the same study
employed Beers criteria 2012 to identify PIM, it found no asso-
ciation between PIM and risk of hospitalization. Though, the
presence of two or more PIMs identified with Beers 2012 and
STOPP 2008 was associated with a higher risk of hospitalization
than the detection of no PIMs.
Two studies examined association between ADR and med-
ication related hospital admission. These studies employed
Naranjo algorithm (an algorithm for determining that an
adverse drug event is due to drug rather than to other factors)
to establish association.11,35
Three studies reported associations between ADR and hospi-
talization. One employed the Algorithm of Krammer (an algo-
rithm for ranking probability of causation between a drug and a
clinical manifestation in an adverse drug reactions).37 A second
study employed clinical pharmacist and geriatrician assessment.5
The third study was by physicians’ diagnosis.49 Two studies iden-
tified ME as the cause of ADR.5,37 Two studies identified death as
a consequence of medicines related hospitalization11,37
The classes of medicines most implicated in the reasons for
hospitalization were non-steroidal anti-inflammatory drugs
1058 titles, abstracts 
and full texts studies
75 potentially included 
full studies
57 full studies 
excluded
983 titles and 
abstracts excluded
21 full studies included
3 studies from 
included Reference list 
search




Figure 1. The PRISMA flow diagram for study selection.
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(NSAIDs),5,11,35,37,45 antiplatelet drugs,11,37,49 diuretics,5,11,35
oral anticoagulants,11,37,49 antidiabetic drugs37,49 and angioten-
sin converting enzyme inhibitors.11,35
Groups most at risk of hospitalization from MRPs were
older people with polypharmacy, impaired renal function, care
needs, mental impairments as well as women.35,37,39 Similarly,
those with comorbidities were reported to be at risk.5,37,45
MRPs in Community Setting
The MRPs reported were ADR,40 PIM34 and ME48
Three single studies examined the association between PIM
and ME respectively with hospital admissions34 use of health
services40 and Medicines Related Hospital Admissions.48These
studies gave conflicting results which were that admission for
fall and for geriatric syndrome were not independently
associated with any markers of suboptimal prescribing.34 How-
ever, number of medicines and use of one or more PIM were
independently associated with all cause admission to hospital
and greater hazard of admission to hospital.34 Similarly, active
failure in medication use process including prescribing, dispen-
sing, administering, and monitoring resulted in drug related
hospital admission.48 Patients with two or more PIP were twice
as likely to have an ADR and have nearly a twofold increased
risk in the expected rate of A&E visit40
Studies on Interventions to Stop MRPs
Studies were undertaken in Canada, Sweden, Taiwan, and UK.
Reported interventions comprised education of service users and
medication review with therapeutic recommendation (Table 3).















1 Hypothesis/aim/objective Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
2 Outcomes Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
3 Patients characteristics described Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
4 Interventions described Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
5 Confounders described No ¼ 0 No ¼ 0 No ¼ 0 No ¼ 0 N0 ¼ 0 No ¼ 0
6 Study findings described Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
7 Estimate of random variability described Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
8 Important adverse events reported Yes ¼ 1 No ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
9 characteristics of patients lost to follow
up reported
No ¼ 0 No ¼ 0 Yes ¼ 1 No ¼ 0 Yes ¼ 1 Yes ¼ 1
10 Actual probability reported Yes ¼ 1 No ¼ 0 No ¼ 0 Yes ¼ 1 Yes ¼ 1 No ¼ 0
11 Representative sample obtained Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yeas ¼ 1
12 Proportion of those asked who agreed to
participate stated
Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
13 Sample drawn from a setting
representative of majority population
Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
14 Attempts made to blind study subject Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 No ¼ 0 Yes ¼ 1
15 Attempts made to blind those measuring
outcomes
No ¼ 0 No ¼ 1 No ¼ 0 No ¼ 0 No ¼ 0 No ¼ 0
16 Was any data dredging reported Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
17 In cohort studies do analysis adjust for
length of follow up
Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
18 Appropriate statistical test used to
measure main outcome
Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
19 Compliance with intervention reliable Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
20 Main outcome measures used accurate Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
21 Patients in different intervention group
similar
Yes ¼ 1 No ¼ 0 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
22 Recruitment to different intervention
group over the same period
Yes ¼ 1 Unable to
determine ¼
0
Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
23 Randomization of study subject done No ¼ 0 No ¼ 0 No ¼ 0 No ¼ 0 No ¼ 0 Yes ¼ 1
24 Concealment of randomized
interventions
No ¼ 0 No ¼ 0 No ¼ 0 No ¼ 0 No ¼ 0 Yes ¼ 1
25 Adequate adjustment for confounding No ¼ 0 No ¼ 0 No ¼ 0 No ¼ 0 No ¼ 0 No ¼ 0










Yes ¼ 1 Unable to
determine ¼ 0
27 Sufficient power Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1 Yes ¼ 1
Total 20 18 20 20 21 22
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Interventions employed in two studies were education of
service users (Taiwan)44,46 and service providers.46 Coaching
rural Taiwanese elders on medication safety44 resulted in an
improvement in medication safety behavior but no apparent
attitude change. However, education of service providers (pre-
scribers) and service users (patients)46 indicated a reduction in
the total number of chronic medication prescribed as well as
participants’ better report on self-health.
Three studies were on medication review with therapeutic
recommendation, Canada,42 Sweden43 and UK.10 Medication
review and reconciliation in addition to patient education, and
therapeutic recommendation to the prescriber resulted in a 16%
reduction in all visit to the hospital, 34% reduction in visit to
the accident and emergency, and an incremental cost saving.43
Applying STOPP/START screening tool followed by recom-
mendations to patient’s doctor demonstrated a reductions in
unnecessary polypharmacy, inappropriate medicines, preva-
lence of falls, all-cause mortality and MRPs with an absolute
risk reduction of 35.7%.10 On the other hand a study with a
relatively small sample size of pharmacist intervention target-
ing polypharmacy in patients with a broad variable health sta-
tus yielded neither a reduction in polypharmacy nor an
improved health outcome.42
Discussion
There is a variation in the prevalence of MRPs reported by
different studies which can be attributed to a number of factors:
Notably, there were variations in types of MRPs, denominator
or population used for calculation, types of tools used for iden-
tification, as well as what data was available to the researchers.
For instance, Endres et al (2016),36 to calculate prevalence
of PIM used as a denominator 392,337 ambulatory patients
aged 65 years and over, who had routine claims data between
January 2009 and December 2010. There was a variation in
prevalence of PIM within this study that ranged from 19.3% to
58.4% depending on the part of year for which PIM was cal-
culated. Their identification tool was the PRISCUS List. On the
other hand, Barnet et al (2011),41 used as a denominator 70299
cohort of older people who were 66 years and over, lived in
either care home or in own home. They reported a PIM pre-
valence of 37.1% for care homes and 30.9% for own homes, not
for a particular period in the year. The findings from these two
studies indicates that those in care (Care home or nursing
homes) can be more at risk of receiving PIM than those that
are not in care (ambulatory patients in their own home). Sec-
ondly, the time of year may have a role in the risk of exposure
to PIM as identified by Endres et al.36 Thus, time of year can
potentially be a confounding factor in exposure to MRPs51
(Pazzagli et al, 2018) Finally, Barnet et al (2011)41 acknowl-
edged that assumptions were made when they encountered
missing data. These assumptions could have impacted on the
calculated prevalence. They identified PIM using Beer’s
Criteria.
The prevalence of ADR related admission was different for
the different studies. Thus, Pirmohamed et al (2004)11 reported
a prevalence of 6.7% while Laatikainen (2016),38 reported a
prevalence of 23.1%. It is worth noting that while these two
studies reported prevalence of events (hospitalization) from
MRPs the other two studies reported prevalence of MRPs
(PIM). Hence prevalence rates would be different.
However, despite significant variations in study designs and
results a clearer picture emerges: Medicines Related Problems
(MRPs) occur across the Primary health care. Across studies,
number of indicators of deterioration associated with MRPs
were between 1 and 3. These include, falls, delirium, use of
health services hospitalization and death. In care homes, com-
mon MRPs reported were Medication error at a prevalence of
up to 69.5%, potentially inappropriate medicines (PIM) at a
prevalence of 20-46%, and adverse drug reaction at a preva-
lence of up to 9.8% per 100 resident months. Residents with
PIM had 33% greater risk of hospitalization and 28% greater
risk of death than those without. The prevalence of PIM among
patients presenting from primary care to hospital was between
23.5% to 48.7%, while that of ADR was between 6.5% to 7.6%.
Findings from other empirical studies and from systematic
reviews suggest that PIM in care homes is a longstanding and
global problem that deserves attention.18,52,53,54 The reported
prevalence of hospitalization associated with MRPs was 5.6%
to 33% for PIM and 5.6% to 37.5% for ADR. This suggests that
the prevalence of hospitalization from MRPs can be similar
across types of MRPs. Errors in prescribing resulted in poten-
tially inappropriate medicines.55 Similarly, for an older person
PIM can result in adverse drug reaction.55,56 This can thus
present a cycle of inappropriateness in medication use for older
people.
Interestingly, findings from two of the included studies pre-
sented conflicting results in terms of the relationship of PIM in
care homes with death and hospitalization. Hence one study
suggested that both hospitalization and death were associated
with PIM.50 On the other hand, another study suggested that no
relationship existed between all cause death and PIM.41 There
are two possible explanations for this, while the participants in
the study that recorded an association were residents in nursing
homes,50 those in the study that recorded no association were
from care homes, nursing homes or from their own homes.41
The participants from nursing homes, can be said to be sicker
and hence more vulnerable to the effect of PIM than partici-
pants who were from care homes and their own homes57 Sec-
ondly, there were differences in the types of medicines
implicated in PIM as studies were conducted in two different
countries, UK, and US, respectively. Studies have indicated
that not all medicines contained in the Beers criteria have rele-
vance in the UK58
Undoubtedly, medication error including PIM is a source of
problem for older people in care homes59,60 as well as in other
settings in the primary care. Inappropriate prescribing is a risk
for medication error and for adverse drug reaction which can
potentially result in deterioration of health indicated by hospi-
talization.61 However, the fact that certain tools like STOPP/
START, the Beers criteria and the PRISCUS List have been
used by researchers and Clinicians in certain settings to identify
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MRPs suggests that applying these tools in routine practice can
be achieved.39,62 The relevance of such practice would be to
support appropriate prescribing hence prevent and reduce poten-
tial deterioration from medicines related problems. In the UK for
instance, the national institute of care and health excellence
(NICE) recommends the use of STOPP/START to support pre-
scribing in order to avoid inappropriate polypharmacy.63
Similar to the findings from this study, that from other single
studies (Bohlken and Kostev, 2018; Onder et al, 2018)64,66 not
includable in this review, also suggest that delirium is associ-
ated with medication use64,65 and that delirium is a risk factor
in falls.66 Therefore, the implication for a patient that has
MRPs associated with delirium is an increased risk of falls. It
is therefore correct to suggest that indicators of deterioration
which are, death, delirium, fall, hospitalization and use of
health services explored in this systematic review can be asso-
ciated with MRPs.
Reported risk factors for MRPs were drug use from
several drug classes, intermittent use of PIM and polyphar-
macy. Reports from other single studies suggest that
polypharmacy is a common problem in care homes glob-
ally.65,67,68 Though, the terminology employed in defining
polypharmacy can vary, what is important is not the number
of medicines but the appropriateness of the medicines.69
However, with an increase in number of medicines there is a
greater opportunity for an inappropriate medicine.41 In addition to
polypharmacy, the other risk factors for hospitalization from
MRPs were age, number of comorbidities, being a woman and
dependent living. Hence a comorbid older patient, with polyphar-
macy, living dependently, if exposed to MRP, will be at a greater
risk of hospitalization.70
The classes of medicines implicated in MRPs were antiplate-
lets, diuretics, NSAIDs, ACEIs, anticoagulants, and hypoglyce-
mics. These are similar to those reported in a review carried out
over a decade ago.71 The fact that following on from a decade
ago, the same classes of medicines are implicated in MRPs can
suggest that monitoring of medication use in older people needs
to be intensified. Finally, narcotics, antihistamines with strong
anticholinergic effects, antispasmodic agents, iron supplements,
anti-infectives and anti-epileptics though not widely reported in
other reviews were identified as implicated in MRPs by this
review. This finding is important because attention is required
in planning interventions for older people.
Tools to identify PIM were Beer’s criteria, STOPP/START
criteria, and the PRISCUSS List. These are clinical tools devel-
oped to assist health care providers in providing safe medicines
to older people. However, the outcome from applying these
tools proved to be context and country related. In addition to
this, the extent to which these tools are applied to support
medication use in primary care is questionable.
Furthermore, preventative interventions to mitigate MRPs,
were mostly successful variations of medication review. Hence
a medication review clinic resulted in a 0.4% reduction in mean
number of medicines and an improvement in general health
ratings of participants from 22% to 38% over a six-month
period.46 Similarly, a study that applied STOPP/START to
identify PIM/PPO coupled with recommendation to a medical
team, reported a reduction in unnecessary polypharmacy from
20.0% at admission to 5.4% at discharge. However, there was a
non-significant reduction in falls and in all-cause mortality
during the 6 months follow up. STOPP/START PIM increased
gradually during the follow up period in both groups.10On the
other hand, a comprehensive medication reconciliation inter-
vention with education and monitoring of the intervention
group and a two month follow up, resulted in an 80% reduction
in drug related admissions.43 The implication is that the inter-
vention that worked well were those that were comprehensive
with an element of patients’ education in addition to an ongoing
conversation with patients.
The systematic review highlights the need for prescribers,
usually medical doctors to reassess prescribing habits and use
appropriate decision tools to optimize prescribing for older
people. Similarly, Pharmacists can apply this tool in optimizing
the medication review process. In addition, pharmacists require
collaborations with Doctors and patients to achieve success in
medication review interventions.
Finally, increase in risks of MRPs with increase in the num-
ber of medicines is of particular relevance to older people who
usually take multiple therapies due to multiple co-morbidities.
Hence the WHO (World Health Organization)15 recognized
Polypharmacy as a priority area in medication safety and in its
mandate “medication without harm” advocates appropriate
interventions to address this globally.
Pharmacists working in collaboration with other health care
professionals have an important role to play in this global
mandate.8
The importance of study finding:
 Reliability of identification tools for PIM can be country
specific according to the included drugs list of the coun-
try. It is important that appropriate tools are used in each
country to achieve reliable outcomes
 Presently, there is considerable variations in reported
outcomes when different tools were employed to inves-
tigate PIM. There is thus a need to standardize systems
as this will allow better comparison of outcomes and
planning of effective interventions
 Reduction in the occurrence of medication errors in pri-
mary care can potentially result in the reduction MRP
outcomes.
 Collaboration among health care professionals and
Patients in planning and executing MRP interventions
is required for optimal results.
 Comorbidity, cognitive impairment, and polypharmacy
appear to be common in people hospitalized due to
MRPs.
 Patients that present with indicators of deterioration
such as falls, delirium, as well as those who without
these, require health care services or hospitalization
should be assessed for medicines related problems. This
can prevent further deterioration if adequate interven-
tion is offered such patients.
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Limitations of the Systematic Review
Searching only published data bases could have resulted in
missing out some potentially relevant but unpublished studies
from the review. Secondly limiting to studies published in
English language could have resulted in missing important
studies published in other languages.
Limitations of the Evidence
To the knowledge of the authors, this is the first systematic
review to assess medicines related problems associated to
potential indicators of deterioration. However, the quality of
available evidence to link these indicators to deterioration in
health are relatively weak. Variation in tools used for identifi-
cation of MRPs limited comparability of findings across
studies.
Comparison with Existing Literature
A few reviews have assessed MRPs in hospitalized patients.
However, none to the knowledge of the reviewers have focused
on MRPs originating in Primary care and associated with
potential indicators of deterioration of health as explored in
this present systematic review.
Implication for Research and Practice
A few studies identified as outcomes, the indicators of dete-
rioration which are relevant to this systematic review. There-
fore, validating the concepts of deterioration in subsequent
studies is required as this will provide measurable indicators
for assessing its prevalence. It will also enable the planning and
evaluation of interventions. Secondly, further research is
required to develop methods for standardized measurements
for medicines related problems that will allow greater compar-
ability of outcomes across studies. Lastly, there was evidence
that medication safety interventions are best achieved with
inputs from all relevant stake holders and that pharmacists have
a role to play in this.
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